Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 16.06.2025 1 AJR Am J Roentgenol 1 Ann Surg Oncol 1 BMC Cancer 1 Br J Cancer 3 Cancer Cell 1 Cancer Lett 1 Cancer Sci 2 Chest 2 Clin Cancer Res 3 Clin Lung Cancer 1 Eur J Cardiothorac Surg 1 Int J Cancer 2 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 1 J Natl Cancer Inst 7 J Thorac Oncol 6 Lung Cancer 1 Mol Carcinog 1 Oncogene 3 PLoS One 2 Proc Natl Acad Sci U S A 1 Science 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. AHN Y, Lee SM, Choe J, Choi S, et al
   Prevalence and Risk Factors for Pathologic N2 Disease in Resected Lung Cancers Assessed as N0 or N1 Disease on Preoperative Imaging.
   AJR Am J Roentgenol. 2025 Feb 19. doi: 10.2214/AJR.24.32486.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. LI Z, Wu J, Chen C, Liu C, et al
   ASO Visual Abstract: Longitudinal Trajectory of Patient-Reported Fatigue in Patients Undergoing Thoracoscopic Lung Cancer Surgery.
   Ann Surg Oncol. 2025 Jun 9. doi: 10.1245/s10434-025-17574.
   PubMed        
   
   

   
   BMC Cancer

3. WANG Y, Su X, Jia J, Zhou T, et al
   Early radiotherapy improved survival of patients with extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy.
   BMC Cancer. 2025;25:1012.
   PubMed         Abstract available
   
   

   
   Br J Cancer

4. GURNEY J, Davies A, Stanley J, Dunn A, et al
   National variation in the treatment of lung cancer in a universal healthcare context.
   Br J Cancer. 2025 Jun 6. doi: 10.1038/s41416-025-03071.
   PubMed         Abstract available
   
   

   
   Cancer Cell

5. ZHU B, Chen P, Aminu M, Li JR, et al
   Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception.
   Cancer Cell. 2025;43:1125-1140.
   PubMed         Abstract available
   
   
6. BALASUBRAMANIAN A, Asselin-Labat ML
   Immune evolution in pre-invasive lung adenocarcinoma.
   Cancer Cell. 2025;43:1004-1006.
   PubMed         Abstract available
   
   
7. GURUNG S, Budden T, Mallela K, Jenkins B, et al
   Stromal lipid species dictate melanoma metastasis and tropism.
   Cancer Cell. 2025;43:1108-1124.
   PubMed         Abstract available
   
   

   
   Cancer Lett

8. JIANG C, He X, Chen X, Huang J, et al
   Lactate accumulation drives hepatocellular carcinoma metastasis through facilitating tumor-derived exosome biogenesis by Rab7A lactylation.
   Cancer Lett. 2025;627:217636.
   PubMed         Abstract available
   
   

   
   Cancer Sci

9. MEN B, Chen Z, Ge H, Yang Z, et al
   Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1.
   Cancer Sci. 2025 Jun 8. doi: 10.1111/cas.70113.
   PubMed         Abstract available
   
   

   
   Chest

10. LI F, Qi L, Xia C, Liu J, et al
    Pulmonary Subsolid Nodules: Upfront Surgery or Watchful Waiting?
    Chest. 2025;167:1764-1777.
    PubMed         Abstract available
    
    
11. YANG BE, Elinoff JM, Campbell-Washburn AE, Wen H, et al
    Evolution of Diffusing Capacity of the Lungs for Carbon Monoxide in Lymphangioleiomyomatosis: Historical Perspectives and the Role of Advanced Imaging.
    Chest. 2025;167:1705-1713.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

12. PAWELETZ CP, Urvalek A, Ha M, Garg K, et al
    Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples.
    Clin Cancer Res. 2025;31:2406-2412.
    PubMed         Abstract available
    
    
13. DAVIES KD
    Finding Rearrangements in the Cell-Free DNA Haystack.
    Clin Cancer Res. 2025;31:2264-2266.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

14. PERUZZO N, Lenz G, Akhiwu T, Bilalaga M, et al
    Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1-Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2025 May 22:S1525-7304(25)00076.
    PubMed         Abstract available
    
    
15. GWIN ME, Prasad T, Wahid U, Bhalla S, et al
    Mortality in a Diverse, Real-World Lung Cancer Screening Cohort.
    Clin Lung Cancer. 2025 May 13:S1525-7304(25)00102.
    PubMed         Abstract available
    
    
16. WATANABE Y, Koide Y, Shimizu H, Aoyama T, et al
    Combined Impact of Coronary Artery Calcification and Heart Radiation Dose on Overall Survival in Locally Advanced Non-Small Cell Lung Cancer: Who Benefits Most from Reducing Heart Radiation Dose?
    Clin Lung Cancer. 2025 May 12:S1525-7304(25)00100.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

17. ZHANG M, Muriana P, Lampridis S, Qu LC, et al
    Prevalence and anatomical characteristics of the left medial basal pulmonary segment: a retrospective cohort study using three-dimensional computed tomography reconstruction.
    Eur J Cardiothorac Surg. 2025;67:ezaf165.
    PubMed         Abstract available
    
    

    
    Int J Cancer

18. ZHAO R, Lu H, Yuan H, Chen S, et al
    Plasma proteomic profiles for early detection and risk stratification of non-small cell lung carcinoma: A prospective cohort study with 52,913 participants.
    Int J Cancer. 2025 Jun 6. doi: 10.1002/ijc.35518.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

19. DOHOPOLSKI M, Schmitt LG, Anand S, Zhang H, et al
    Exploratory Evaluation of Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR) with CNS-Active Drugs in Brain Metastases Treatment.
    Int J Radiat Oncol Biol Phys. 2024 Nov 16:S0360-3016(24)03641.
    PubMed         Abstract available
    
    
20. AKDEMIR EY, Herrera R, Gurdikyan S, Hodgson LC, et al
    Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Infradiaphragmatic Oligometastatic Disease: Disrupting the One-Size-Fits-All Paradigm.
    Int J Radiat Oncol Biol Phys. 2025;122:739-751.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

21. PIOTROWSKA Z, Passaro A, Nguyen D, Ruiter G, et al
    Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab.
    J Clin Oncol. 2025 Jun 1:JCO2500763. doi: 10.1200/JCO-25-00763.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

22. KANAYA N, Seddiq W, Chen KS, Kajiwara Y, et al
    Engineered allogeneic stem cells orchestrate T lymphocyte driven immunotherapy in immunosuppressive leptomeningeal brain metastasis.
    J Natl Cancer Inst. 2025 Jan 22:djaf006. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

23. MAO S, Liu X, Wang L, Wang Y, et al
    AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC.
    J Thorac Oncol. 2025;20:739-749.
    PubMed         Abstract available
    
    
24. SPIRA AI, Paz-Ares L, Han JY, Shih JY, et al
    Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report.
    J Thorac Oncol. 2025;20:809-816.
    PubMed         Abstract available
    
    
25. SCHEFFLER M, Wolf J, Michels S
    Can Immunotherapy Be Omitted in KRAS G12C-Mutant Lung Cancer by 2025?
    J Thorac Oncol. 2025;20:692-694.
    PubMed        
    
    
26. FU F, Chen H
    Bridging the Gap in Surgery for Octogenarians With Early-Stage Lung Cancer.
    J Thorac Oncol. 2025;20:703-704.
    PubMed        
    
    
27. REVEL MP
    Overcoming Barriers to Lung Cancer Screening: The Incidental Pulmonary Nodule Strategy.
    J Thorac Oncol. 2025;20:705-707.
    PubMed        
    
    
28. MEERBEECK JV, Hal GV, Snoeckx A
    Quality Performance Indicators for Lung Cancer Screening: Towards the Next Levels?
    J Thorac Oncol. 2025;20:e68-e69.
    PubMed        
    
    
29. TAMMEMAGI MC, Borondy-Kitts A, Field JF, Mohan A, et al
    A Response to the Letter to the Editor: "Quality Performance Indicators for Lung Cancer Screening: Towards the Next Levels?".
    J Thorac Oncol. 2025;20:e69-e71.
    PubMed        
    
    

    
    Lung Cancer

30. SRIDHAR A, Adjei A, Montori VM, Leventakos K, et al
    Shared decision making for personalized lung cancer care.
    Lung Cancer. 2025 Jun 9:108614. doi: 10.1016/j.lungcan.2025.108614.
    PubMed        
    
    
31. GUDINA AT, Fitzgibbon ML, Peterson CE, Byrne C, et al
    Geographic disparities in lung cancer screening uptake in the United States using the 2021 United States Preventive Services Task Force Guidelines.
    Lung Cancer. 2025;205:108615.
    PubMed         Abstract available
    
    
32. KRAYIM B, Shalata W, Bar J, Moskovitz M, et al
    Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes.
    Lung Cancer. 2025;205:108598.
    PubMed         Abstract available
    
    
33. ZHANG Q, Yang Y, Xie M, Zhou Z, et al
    Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases.
    Lung Cancer. 2025;205:108616.
    PubMed         Abstract available
    
    
34. NAIDU SB, Bhamani A, Murray C, Beyer K, et al
    AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium.
    Lung Cancer. 2025;205:108610.
    PubMed         Abstract available
    
    
35. FUJISAKI T, Miyauchi E, Kida G, Miura Y, et al
    Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis.
    Lung Cancer. 2025;205:108597.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

36. CAO L, Xu H, Zhang A, Gao L, et al
    LINC02562 Promotes Progression of Lung Cancer by Regulating NTHL1 Dependent DNA Damage Repair Mechanisms.
    Mol Carcinog. 2025 Jun 11. doi: 10.1002/mc.23935.
    PubMed         Abstract available
    
    

    
    Oncogene

37. POIRIER A, Utecht T, Villot R, Gelinas Y, et al
    ZNF768 loss amplifies p53 action and reduces lung tumorigenesis in mice.
    Oncogene. 2025;44:1793-1804.
    PubMed         Abstract available
    
    

    
    PLoS One

38. ZHENG Z, Zhu H, Fang L
    Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
    PLoS One. 2025;20:e0325171.
    PubMed         Abstract available
    
    
39. WANG X, Sharpnack J, Lee TCM
    Improving lung cancer diagnosis and survival prediction with deep learning and CT imaging.
    PLoS One. 2025;20:e0323174.
    PubMed         Abstract available
    
    
40. ABUMANSOUR H, Abusara OH, Abu-Sini M, Khalil W, et al
    Thionated levofloxacin derivative: Potential repurposing for cancer treatment and synergism with doxorubicin on doxorubicin-resistant lung cancer cells.
    PLoS One. 2025;20:e0324930.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

41. WANG M, Wang Y, Pan X, Wang B, et al
    Acquired resistance to immunotherapy by physical barriers with cancer cell-expressing collagens in non-small cell lung cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2500019122.
    PubMed         Abstract available
    
    
42. GORELIK A, Paulo JA, Schroeter CB, Lad M, et al
    CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor-driven proteome through PARP7 activity.
    Proc Natl Acad Sci U S A. 2025;122:e2424985122.
    PubMed         Abstract available
    
    

    
    Science

43. GOMEZ-LOPEZ S, Alhendi ASN, Przybilla MJ, Bordeu I, et al
    Aberrant basal cell clonal dynamics shape early lung carcinogenesis.
    Science. 2025;388:eads9145.
    PubMed         Abstract available
    
    

    
    Thorax

44. TEN HAAF K
    Towards dynamic risk assessments in lung cancer screening.
    Thorax. 2025 Jun 8:thorax-2025-223403. doi: 10.1136/thorax-2025-223403.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.